Renaissance Technologies LLC Increases Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO)

Renaissance Technologies LLC grew its position in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 87.2% during the second quarter, according to its most recent filing with the SEC. The firm owned 438,200 shares of the company’s stock after acquiring an additional 204,100 shares during the period. Renaissance Technologies LLC owned about 0.84% of ALX Oncology worth $2,642,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in ALXO. Vestal Point Capital LP bought a new position in ALX Oncology in the 4th quarter valued at approximately $24,643,000. Redmile Group LLC lifted its holdings in shares of ALX Oncology by 18.2% during the 1st quarter. Redmile Group LLC now owns 4,326,509 shares of the company’s stock valued at $48,241,000 after buying an additional 667,245 shares during the period. Privium Fund Management B.V. purchased a new stake in shares of ALX Oncology in the 2nd quarter worth $2,271,000. TD Asset Management Inc purchased a new position in shares of ALX Oncology during the 4th quarter valued at about $1,048,000. Finally, Vanguard Group Inc. grew its stake in shares of ALX Oncology by 4.3% during the 1st quarter. Vanguard Group Inc. now owns 1,566,464 shares of the company’s stock valued at $17,466,000 after acquiring an additional 64,055 shares during the period. 97.97% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider Jaume Pons sold 20,000 shares of ALX Oncology stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $7.90, for a total transaction of $158,000.00. Following the completion of the sale, the insider now owns 593,447 shares of the company’s stock, valued at $4,688,231.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 23,752 shares of company stock valued at $173,003 over the last quarter. 33.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently commented on ALXO shares. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a report on Monday, August 12th. UBS Group lowered their price target on ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 16th. Stifel Nicolaus reaffirmed a “hold” rating and set a $3.00 price objective (down from $5.00) on shares of ALX Oncology in a report on Friday, August 9th. Lifesci Capital lowered ALX Oncology from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 31st. Finally, HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of ALX Oncology in a report on Tuesday, August 13th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

ALX Oncology Stock Performance

Shares of ALX Oncology stock opened at $1.86 on Wednesday. The stock’s fifty day moving average price is $2.72 and its 200-day moving average price is $8.15. ALX Oncology Holdings Inc. has a 12 month low of $1.76 and a 12 month high of $17.83. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.06. The firm has a market cap of $96.91 million, a P/E ratio of -0.50 and a beta of 1.01.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.01. On average, equities research analysts expect that ALX Oncology Holdings Inc. will post -3.04 earnings per share for the current fiscal year.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.